Federal Supply Schedule 36F79719D0217

The federal contract IDV award is a multiple award blanket purchase agreement between the Department of Veterans Affairs Veterans Health Administration and Janssen Biotech, Inc. The BPA utilizes Janssen's Pharmaceuticals and Drugs Federal Supply Schedule, referred to as FSS-61-IB, to provide for the delivery of Balversa and Belzutifan medications to various Veterans Integrated Service Networks. Delivery locations under the BPA include Carrollton, Texas; Chelsea, Maine; and Horsham, Pennsylvania to support VISNs 1, 9, and 23. Performance periods and contract values for individual delivery orders issued against the BPA range from approximately October 2020 to July 2024, and $11,000 to $90,000, respectively. Collectively valued at $3.7 million, the single award BPAs aim to ensure continued cancer care treatment for veterans by providing regional VA medical centers a streamlined means of procuring specialized oncology pharmaceuticals from Janssen Biotech as the prime contractor.

The original solicitation sought a pharmaceutical and drugs Federal Supply Schedule to facilitate the Veterans Health Administration's procurement of prescription medications. Task orders issued against the BPA and under the FSS contract provide Balversa and Belzutifan to VA medical facilities, with no set-aside designations applied. As one of the largest integrated healthcare systems, the VHA utilizes contracts such as these blanket purchase agreements to maintain access to critical supplies and ensure eligible veterans receive comprehensive medical services through its network of medical centers and outpatient clinics.